Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722

Show all 309 references

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne‐Jones, R., Wyrwicz, L. S., Tiret, E., Brown, G. M., Rödel, C. M., Cervantes, A. M. R., & Arnold, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx224 · Cited by 2,098
Self-citation
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Self-citation
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,737
Self-citation
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Colorectal cancer liver metastases – a population-based study on incidence, management and survival
Engstrand, J., Nilsson, H., Strömberg, C., Jonas, E., & Freedman, J. (2018) · BMC Cancer · doi:10.1186/s12885-017-3925-x · Cited by 902
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H., Venook, A. P., Heinemann, V., Cutsem, E. V., Pignon, J., Tabernero, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 853
Self-citation
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Self-citation
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Self-citation
Early‐onset colorectal cancer in young individuals
Mauri, G., Bianchi, A. S., Russo, A. G., Marsoni, S., Bardelli, A., & Siena, S. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12417 · Cited by 653
Self-citation
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Self-citation
Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update
Izzo, F., Granata, V., Grassi, R., Fusco, R., Palaia, R., Delrio, P., Carrafiello, G., Azoulay, D., Petrillo, A., & Curley, S. A. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0337 · Cited by 581
Liver metastases
Tsilimigras, D. I., Brodt, P., Clavien, P., Muschel, R. J., D'Angelica, M. I., Endo, I., Parks, R. W., Doyle, M. B., de Santibáñes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 584
DNA mismatch repair in cancer
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 574
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 556
Self-citation
Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer
Li, W., Zhou, C., Yu, L., Hou, Z., Liu, H., Kong, L.-H., Xu, Y., He, J., Jin, L., Ou, Q., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2249762 · Cited by 502
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & SUKOR, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 470
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Self-citation
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Siena, S., Bartolomeo, M. D., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Élez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 436
Self-citation
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Gut microbiome and its role in colorectal cancer
Reberšek, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-09054-2 · Cited by 365
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Finn, R. S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347
Self-citation
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
Vidal, J., Muinelo, L., Dalmases, A., Jones, F. S., Edelstein, D. L., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 345
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial
Cremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30862-9 · Cited by 334
Self-citation
Treatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Bianchi, A. S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 337
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Loree, J. M., Pereira, A. A. L., Lam, M. S., Willauer, A. N., Raghav, K. P. S., Dasari, A. N., Morris, V. K., Advani, S., Menter, D. G., Eng, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2484 · Cited by 316
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 310
Self-citation
Young-onset colorectal cancer
Spaander, M. C. W., Zauber, A. G., Syngal, S., Blaser, M. J., Sung, J. J. �., You, Y. N., & Kuipers, E. J. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00432-7 · Cited by 319
Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?
Stewart, C. L., Warner, S. G., Ito, K., Raoof, M., Wu, G. X., Kessler, J., Kim, J. Y., & Fong, Y. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.08.004 · Cited by 291
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 278
Self-citation
Colorectal liver metastases: Current management and future perspectives
Martin, J. L., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S. A., Cheow, H. K., Duckworth, A., Heister, P. M., Praseedom, R., Jah, A., et al. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i10.761 · Cited by 294
Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance
Tuomisto, A., Mäkinen, M. J., & Väyrynen, J. P. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i31.4383 · Cited by 285
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
Xu, J., Kim, T. W., Shen, L., Sriuranpong, V., Pan, H., Xu, R., Guo, W., Han, S., Liu, T., Park, Y. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3245 · Cited by 266
Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123733 · Cited by 262
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
Qin, S., Li, J., Wang, L., Xu, J., Cheng, Y., Bai, Y., Li, W., Xu, N., Lin, L.-Z., Wu, Q., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3183 · Cited by 237
Determinants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 262
Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Garlan, F., Laurent‐Puig, P., Sefrioui, D., Siauve, N., Didelot, A., Sarafan‐Vasseur, N., Michel, P., Perkins, G., Mulot, C., Blons, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3155 · Cited by 250
Self-citation
Modern therapeutic approaches for the treatment of malignant liver tumours
Petrowsky, H., Fritsch, R., Gückenberger, M., Oliveira, M. L. D., Dutkowski, P., & Clavien, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0314-8 · Cited by 252
Pathological Features and Prognostication in Colorectal Cancer
Chen, K., Collins, G. P., Wang, H., & Toh, J. W. T. (2021) · Current Oncology · doi:10.3390/curroncol28060447 · Cited by 260
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Bianchi, A. S., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F. M., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 254
Self-citation
S3-Leitlinie – Kolorektales Karzinom
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T. G., Nothacker, M., Porschen, R., Rödel, C. M., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 247
Self-citation
Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline
Chiorean, E. G., Nandakumar, G., Fadelu, T. A., Temin, S., Alarcon-Rozas, A. E., Bejarano, S., Croitoru, A. E., Grover, S., Lohar, P. V., Odhiambo, A. O., et al. (2020) · JCO Global Oncology · doi:10.1200/jgo.19.00367 · Cited by 244
Precision oncology in metastatic colorectal cancer — from biology to medicine
Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 244
Self-citation
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial
Pfeiffer, P., Yilmaz, M., Möller, S., Zitnjak, D., Krogh, M., Petersen, L. N., Poulsen, L. Ø., Winther, S. B., Thomsen, K. G., & Qvortrup, C. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30827-7 · Cited by 232
Self-citation
Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches
Saman, H. T., Raza, S. S., Shahab Uddin, M. S., & Rasul, K. I. (2020) · Cancers · doi:10.3390/cancers12051172 · Cited by 258
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Cremolini, C., Antoniotti, C., Stein, A., Bendell, J. C., Gruenberger, T., Rossini, D., Masi, G., Ongaro, E., Hurwitz, H. I., Falcone, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01225 · Cited by 241
Self-citation
Colorectal liver metastases: An update on multidisciplinary approach
Chow, F. C.-L., & Chok, K. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i2.150 · Cited by 236
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225
Self-citation
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): An open-label, randomised, phase 3 trial
Andre, T., Amonkar, M., Norquist, J. M., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D., Garcia-Carbonero, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00064-4 · Cited by 209
Self-citation
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224
Self-citation
General insight into cancer: An overview of colorectal cancer (Review)
Alzahrani, S. M., Doghaither, H. A. A., & Al-Ghafari, A. B. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2433 · Cited by 242
Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Hofheinz, R., Fokas, E., Benhaïm, L., Price, T. J., Arnold, D., Beets‐Tan, R. G. H., Guren, M. G., Hospers, G. A. P., Lonardi, S., Nagtegaal, I. D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.528 · Cited by 235
Self-citation
Expert Consensus Document on Pulmonary Metastasectomy
Handy, J. R., Bremner, R. M., Crocenzi, T. S., Detterbeck, F. C., Fernando, H. C., Fidias, P. M., Firestone, S., Johnstone, C. A., Lanuti, M. D., Litle, V. R., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.10.028 · Cited by 211
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
García‐Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z. A., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 207
Self-citation
Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
Oliveira, A., Bretes, L., & Furtado, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00396 · Cited by 199
Hepatic metastasis from colorectal cancer
Kow, A. W. C. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.08.06 · Cited by 199
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
Stintzing, S., Wirapati, P., Lenz, H., Neureiter, D., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al‐Batran, S., Heintges, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz387 · Cited by 196
Self-citation
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
Modest, D. P., Martens, U. M., Riera‐Knorrenschild, J., Greeve, J. C., Florschütz, A., Weßendorf, S., Ettrich, T. J., Kanzler, S., Nörenberg, D., Ricke, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01340 · Cited by 195
Self-citation
Survival improvement for patients with metastatic colorectal cancer over twenty years
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00353-4 · Cited by 192
Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines
Bonney, G. K., Chew, C. A. Z., Lodge, P. A., Hubbard, J. M., Halazun, K. J., Trunečka, P., Muiesan, P., Mirza, D. F., Isaac, J., Laing, R. W., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00219-3 · Cited by 191
Self-citation
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
Tie, J., Wang, Y., Cohen, J. D., Li, L., Hong, W., Christie, M., Wong, H., Kosmider, S., Wong, R., Thomson, B. N. J., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003620 · Cited by 189
CIRSE Standards of Practice on Thermal Ablation of Liver Tumours
Crocetti, L., de Baère, T., Pereira, P. L., & Tarantino, F. P. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02471-z · Cited by 181
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
Kuboki, Y., Nishina, T., Shinozaki, E., Yamazaki, K., Shitara, K., Okamoto, W., Kajiwara, T., Matsumoto, T., Tsushima, T., Mochizuki, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30425-4 · Cited by 180
Self-citation
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
Bachet, J., Bouché, O., Taı̈eb, J., Dubreuil, O., Garcia‐Larnicol, M., Meurisse, A., Normand, C., Gornet, J., Artru, P., Louafi, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy061 · Cited by 178
Self-citation
International Journal of Clinical Oncology
(2013) · International Journal of Clinical Oncology · doi:10.1007/10147.1437-7772 · Cited by 175
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
Heinemann, V., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., Seipelt, G., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01140-9 · Cited by 173
Self-citation
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178
Self-citation
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway
Xu, X., Lv, J., Guo, F., Li, J., Jia, Y., Jiang, D., Wang, N., Zhang, C., Kong, L., Liu, Y., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00814 · Cited by 173
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Porru, M., Pompili, L., Caruso, C., Biroccio, A., & Leonetti, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0719-1 · Cited by 181
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Markham, M. J., WACHTER, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C., Galindo, C. R., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 181
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Rosen, L. S., Jacobs, I. A., & Burkes, R. L. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0518-1 · Cited by 172
Making Meaningful Clinical Use of Biomarkers
Selleck, M. J., Senthil, M., & Wall, N. R. (2017) · Biomarker Insights · doi:10.1177/1177271917715236 · Cited by 169
Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy
Auclin, É., Zaanan, A., Vernerey, D., Douard, R., Gallois, C., Laurent‐Puig, P., Bonnetain, F., & Taı̈eb, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx030 · Cited by 159
Self-citation
The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases
Bălăcescu, O., Sur, D. G., Cainap, C. I., Vișan, S., Cruceriu, D., Manzat-Saplacan, R. M., Muresan, M.-S., Bălăcescu, L., Lisencu, C. I., & Irimie, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123711 · Cited by 161
Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
Zhang, X., Wu, T., Cai, X., Dong, J., Xia, C., Zhou, Y., Ding, R., Yang, R., Tan, J., Zhang, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795972 · Cited by 162
Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer
Okita, A., Takahashi, S. I., Ouchi, K., Inoue, M., Watanabe, M., Endo, M., Honda, H., Yamada, Y., & Ishioka, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24617 · Cited by 162
The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases
Andratschke, N. H., Alheid, H., Allgäuer, M., Becker, G., Blanck, O., Boda‐Heggemann, J., Brunner, T. B., Duma, M. N., Gerum, S., Gückenberger, M., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4191-2 · Cited by 157
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
Xu, R., Muro, K., Morita, S., Iwasa, S., Han, S., Wang, W., Kotaka, M., Nakamura, M., Ahn, J. B., Deng, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30140-2 · Cited by 153
Self-citation
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines
Cavestro, G. M., Mannucci, A., Balaguer, F., Hampel, H., Kupfer, S. S., Repici, A., Bianchi, A. S., Seppälä, T. T., Valentini, V., Boland, C. R., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.12.006 · Cited by 151
The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor
Xie, Q., Chen, P., Hu, W., Sun, P., He, W., Jiang, C., Kong, P., Liu, S., Chen, H., Yang, Y., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1638-9 · Cited by 152
Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer
Montroni, I., Ugolini, G., Saur, N. M., Spinelli, A., Rostoft, S., Millán, M., Wolthuis, A. M., Daniels, I. R., Hompes, R., Penna, M., et al. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.08.003 · Cited by 145
Self-citation
Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)
Araghi, M., Arnold, M., Rutherford, M. J., Guren, M. G., Cabasag, C. J., Bardot, A., Ferlay, J., Tervonen, H. E., Shack, L., Woods, R. R., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320625 · Cited by 146
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Van Cutsem, E., Martinelli, E., Cascinu, S., Sobrero, A., Banzi, M., Seitz, J.-F., Barone, C., Ychou, M., Peeters, M., Brenner, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0072 · Cited by 142
Self-citation
Therapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 151
Self-citation
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
Stintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 138
Self-citation
Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group
deSouza, N. M., Liu, Y., Chiti, A., Oprea‐Lager, D. E., Gebhart, G., BEERS, B. E. V., Herrmann, K., & Lecouvet, F. E. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.012 · Cited by 138
The current status of treatment for colorectal cancer in China
Zhang, Y., Chen, Z., & Li, J. (2017) · Medicine · doi:10.1097/md.0000000000008242 · Cited by 135
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies
Vogel, A., Hofheinz, R., Kubicka, S., & Arnold, D. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.007 · Cited by 135
Self-citation
Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy
Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122
Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases
Wang, C., Sandhu, J. S., Ouyang, C., Ye, J., Lee, P. P., & Fakih, M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18416 · Cited by 136
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02696-8 · Cited by 144
“Patients with CRC who have tumors harboring a KRAS mutation (including KRAS G12C ) do not benefit and thus are not eligible for anti-epidermal growth factor receptor-based therapies 8,9 .”
BackgroundSelf-citation
Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival
Calandri, M., Yamashita, S., Gazzera, C., Fonio, P., Veltri, A., Bustreo, S., Sheth, R. A., Yevich, S. M., Vauthey, J., & Odisio, B. C. (2018) · European Radiology · doi:10.1007/s00330-017-5273-2 · Cited by 130
Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study
Majano, S. B., Girolamo, C. D., Rachet, B., Maringe, C., Guren, M. G., Glimelius, B. L. G., Iversen, L. H., Schnell, E. A., Lundqvist, K., Christensen, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30646-6 · Cited by 132
The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Germano, G., Amirouchene-Angelozzi, N., Rospo, G., & Bardelli, A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0150 · Cited by 130
Self-citation
Current Targeted Therapy for Metastatic Colorectal Cancer
Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 138
CD44v6 engages in colorectal cancer progression
Ma, L., Dong, L., & Chang, P. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1265-7 · Cited by 128

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks